Outpatient Oncology Unit, Kyoto University Hospital, 54 Shogin-Kawahara-cho, Sakyo-ku, Kyoto, Japan.
Br J Cancer. 2011 Nov 22;105(11):1693-6. doi: 10.1038/bjc.2011.398. Epub 2011 Oct 27.
A blood pressure drop after bevacizumab administration and its clinical significance have not been previously reported.
Blood pressure data at 0, 90, and 180 min after a total of 162 bevacizumab administrations in 81 advanced colorectal cancer patients were retrospectively investigated.
Twenty-five patients (30%) demonstrated an average temporary drop of 20 mm Hg or more in systolic blood pressure. We classified these 25 patients as group A and the others as group B. Median time-to-treatment failure (TTF) was significantly longer in group A than in group B (291 vs 162 days; P=0.02). Furthermore, the proportion of patients who required intervention with antihypertensive drugs during bevacizumab treatment was significantly higher in group A than in group B (36% vs 4%; P<0.01).
This study suggests that a temporary blood pressure drop after bevacizumab administration could be a predictive marker for bevacizumab treatment.
贝伐珠单抗给药后血压下降及其临床意义尚未见报道。
回顾性分析 81 例晚期结直肠癌患者共 162 次贝伐珠单抗给药后 0、90 和 180 分钟的血压数据。
25 例患者（30%）的收缩压平均暂时下降 20mmHg 或更多。我们将这 25 例患者分为 A 组，其余患者分为 B 组。A 组的中位无进展生存期（TTF）明显长于 B 组（291 天 vs 162 天；P=0.02）。此外，A 组在贝伐珠单抗治疗期间需要用降压药干预的患者比例明显高于 B 组（36% vs 4%；P<0.01）。
本研究表明，贝伐珠单抗给药后血压暂时下降可能是贝伐珠单抗治疗的预测标志物。
